Popular Articles
-
Organizations in the News
(63 articles) Thoraxcenter at Erasmus University Medical Center
(52 articles) Massachusetts General Hospital
(48 articles) Harvard University
(37 articles) Case Western Reserve University
(34 articles) Wakayama Medical University
(27 articles) Cardiovascular Research Foundation
(22 articles) Royal Brompton Hospital
-
People in the News
(60 articles) Scott Huennekens
(56 articles) Patrick W. Serruys
-
St. Jude, Volcano battle in court over FFR technology
Explore Article Cardiovascularbusiness.com (20 hours, 26 min ago)
St. Jude Medical has filed a lawsuit against Volcano for patent infringement, including its PrimeWire pressure guidewire products, infringe on patents used for St. Jude’s PressureWire technology platform, which was acquired from Radi Medical Systems. In response, Volcano said it will “vigorously defend” itself against the lawsuit. The suit involves five St. Jude patents and seeks injunctive relief and monetary damages, according to the St. Paul, Minn.-based company. The PressureWire interventional technology measures fractional flow reserve (FFR).
Comment on Article Mentions: LightLab Imaging Axsun Technologies St. Jude Medical
-
Volcano Corporation (VOLC) Stock Trades Below the 50-Day Moving Average
Explore Article Market Intellisearch (20 hours, 49 min ago)
NEW YORK (Market Intellisearch) -- Shares of Volcano Corporation settled at $21.30 down $1.19(-5.29%) in today's trading session. On the volume front, trading was heavier than usual and the price of VOLC shares crossed below the 50-day moving average of $22.37. The relationship between the stock's price and its moving average is key to determining the trend. Today's trading activity is a sign that the shares of VOLC may continue to head lower in the near future as long as the moving average continues to decrease.
Comment on Article Mentions: Volcano
-
Medical Device Battle: Can St. Jude Bigfoot Volcano? (CNBC Video)
Explore Article cnbc.com (Jul 28 2010)
This is one of those corporate battles that sometimes falls through the reporting cracks, but shouldn't. In one corner we have St. Jude Medical, the big medical device company. In the other: Volcano Corporation, which has been rapidly growing with several specialty products. Volcano's biggest product is intravascular ultrasound, which is used to help in the placement of heart stents. It's also big in something called fractional flow reserve, or FFR, which can help determine if you're going to have a heart attack and need a stent or surgery. The company’s goal is to make IVUS, as it is called, ...
Comment on Article Mentions: St. Jude Medical Volcano LightLab Imaging
-
St. Jude Medical Files Patent Infringement Lawsuit Against Volcano Corporation in the U.S.
Explore Article Optical Coherence Tomography News (Jul 28 2010)
ST. PAUL, Minn. St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, announced today that it has filed a lawsuit against Volcano Corporation for patent infringement. The suit, which involves five St. Jude Medical patents and seeks injunctive relief and monetary damages, was filed in t
Comment on Article Mentions: Volcano St. Jude Medical LightLab Imaging
-
Volcano Will Strongly Defend Against St. Jude Lawsuit
Explore Article PR Newswire (Jul 27 2010)
SAN DIEGO, July 27 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC) stated today that it will vigorously defend against the patent infringement lawsuit filed against it by St. Jude Medical in federal district court in Delaware. Volcano believes that the claims against it are entirely without merit, and looks forward to vindicating its rights in court. The Complaint filed today has nothing to do with other litigation between the parties, including the action pending in Suffolk Superior Court in Massachusetts, in which no judgment has been entered and trial is still ongoing, and the action brought by Volcano in Delaware Chancery ...
Comment on Article Mentions: Axsun Technologies St. Jude Medical Volcano
-
St. Jude Medical alleges patent infringement, stolen trade secrets
Explore Article massdevice.com (Jul 27 2010)
St. Jude Medical Inc. files a patent infringement lawsuit against Volcano Corp. over cardiac guidewires and accuses a former group president of pilfering trade secrets in his move to crosstown rival Medtronic Inc. St. Jude Medical Inc. (NYSE: STJ) filed a pair of lawsuits accusing two of its rivals of patent infringement and stealing trade secrets. The Little Canada, Minn.-based medical device maker filed a lawsuit against Volcano Corp. (NSDQ:VOLC) in the U.S. District Court for Delaware, accusing it of violating a quintet of patents St. Jude acquired in its 2008 buyout of Radi Medical Systems AB, a Swedish guidewire ...
Comment on Article Mentions: St. Jude Medical LightLab Imaging Volcano
-
St. Jude posts double-digit gains in sales, income for Q2
Explore Article CMIO.net (Jul 25 2010)
St. Jude Medical has reported double-digit increase of sales and net earnings for the second quarter, which ended July 3. Net earnings for the second quarter of 2010 were $254 million, compared with net earnings for the second quarter of 2009 of $219 million, the St. Paul, Minn.-based company reported. St. Jude recorded net sales of $1.31 billion in the second quarter of 2010, an increase of 11 percent compared with the $1.18 billion in the second quarter of 2009.
Comment on Article Mentions: LightLab Imaging Boston Scientific Daniel J. Starks
-
Strut Coverage and Vessel Wall Response to a New-Generation Paclitaxel-Eluting Stent With an Ultrathin Biodegradable Abluminal Polymer: Optical Coherence Tomography Drug-Eluting Stent Investigation (OCTDESI)
Explore Article Circulation (Jul 22 2010)
Background—Polymer-coated drug-eluting stents are effective in preventing restenosis but have been associated with delayed healing and incomplete strut coverage. It is unknown whether paclitaxel-eluting stents (PES) with minimal biodegradable abluminal coating enhances strut coverage while preventing neointimal hyperplasia. Using optical coherence tomography (OCT) as a primary imaging modality, we assessed the proportion of uncovered struts at 6-month follow-up in PES coated with durable versus ultrathin (<1 µ m) biodegradable abluminal polymers. Methods and Results—In this pilot trial, 60 patients with de novo lesions (25 mm) in native coronary vessels were randomly assigned to receive either TAXUS Liberté PES or JACTAX ...
Comment on Article Mentions: Case Western Reserve University Boston Scientific Marco A. Costa
-
St. Jude Medical CEO: second quarter was “absolutely awesome”
Explore Article MedCity News (Jul 22 2010)
Normally, you wouldn’t expect the CEO of a major medical device company to employ the phrase “absolutely awesome” during a conference call with Wall Street analysts. But then again, you really can’t blame St. Jude Medical Inc. (NYSE: STJ) CEO Dan Starks for showing a little enthusiasm. Starks was specifically referring to the initial sales of the company’s newest initial cardioverter defibrillators (ICDs) but he might as well been describing STJ’s second quarter performance. In short, STJ kicked major butt, especially in its core ICD and pacemaker business. The company said second quarter profits soared nearly 16 percent to $254 ...
Comment on Article Mentions: LightLab Imaging Boston Scientific St. Jude Medical
-
Volcano Corporation Schedules Second Quarter Conference Call, Webcast
Explore Article ptca.org (Jul 20 2010)
July 20, 2010 -- San Diego -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced that it will report its operating results for the second quarter and first six months of fiscal 2010 on Friday, July 30.
Comment on Article Mentions: Volcano John Dahldorf Scott Huennekens
-
Clinical Classification and Plaque Morphology Determined by Optical Coherence Tomography in Unstable Angina Pectoris
Explore Article American Journal of Cardiology (Jul 20 2010)
Unstable angina pectoris (UAP) is categorized with the Braunwald classification. However, the association of clinical presentation and plaque structure/function has not yet been elucidated in relation to cause. We used optical coherence tomography to investigate this relation. One hundred fifteen patients with primary UAP were categorized according to the Braunwald classification. Patients with class I UAP had the highest frequency of ulcers without fibrous cap disruption (p = 0.003) and the smallest minimum lumen area (class I, median 0.70 mm2, quartiles 1 to 3 0.42 to 1.00; class II, 1.80 mm2, 1.50 to 2.50; class III, 2.31 mm2, 1.21 to ...
Comment on Article Mentions: Wakayama Medical University Takashi Kubo Shigeho Takarada
-
Method and apparatus for viewing through blood
Explore Article uspto.gov (Jul 20 2010)
A method, apparatus, and system for viewing through blood in situ including a flexible catheter for insertion into a blood vessel, an optical assembly positioned at the distal end of the catheter, a working channel, and a control unit for regulating the opacity level of blood in the blood vessel around the distal end of the catheter and controllably injecting quantities of fluid into the blood vessel in the vicinity of the optical assembly. A local controller located at the distal end of the catheter may control functions of the optical assembly while coordinating signals and power with the control ...
-
The Effect of Lipid and Inflammatory Profiles on the Morphological Changes of Lipid-Rich Plaques in Patients With Non-ST-Segment Elevated Acute Coronary Syndrome: Follow-Up Study by Optical Coherence Tomography and Intravascular Ultrasound
Explore Article interventions.onlinejacc.org (Jul 19 2010)
Objectives The aim of this study was to determine the relationship between the morphological changes of nonculprit lipid-rich plaques and several clinical profiles in patients with non–ST-segment elevated acute coronary syndrome (NSTEACS). Background Identification of coronary lesion with morphological characteristics of rupture-prone plaques is still difficult. Methods Eighty-two consecutive patients with NSTEACS who underwent percutaneous coronary intervention were enrolled. The changes in total atheroma volume (TAV) of residual nonculprit lipid-rich plaques and the changes in the corresponding fibrous cap thickness (FCT) were assessed by intravascular ultrasound and optical coherence tomography, respectively, at baseline and after 9 months. Results The percentage ...
Comment on Article Mentions: Takashi Akasaka Hironori Kitabata Takashi Kubo
-
Development of lipid-rich plaque inside bare metal stent: possible mechanism of late stent thrombosis? An optical coherence tomography study
Explore Article Heart (Jul 16 2010)
Aims To study in-stent tissue characteristics by optical coherence tomography (OCT) at long-term follow-up in patients with previous bare metal stent implantation. Methods and results Among 1636 patients who underwent bare metal stent (BMS) implantation between 1999 and 2006, 39 patients with 60 BMS who developed recurrent ischaemia underwent repeat catheterisation and OCT imaging between June 2008 and August 2009. The average time interval between initial BMS implantation and OCT imaging was 6.5±1.3 years. A lesion that had features of lipid-rich plaque was found in 20 stents (33.3%) in 16 patients (41%). Fibrous intima was observed in the remaining 40 ...
Comment on Article Mentions: LightLab Imaging Massachusetts General Hospital Ik-Kyung Jang
-
Comparisons of Baseline Demographics, Clinical Presentation, and Long-Term Outcome Among Patients With Early, Late, and Very Late Stent Thrombosis of Sirolimus-Eluting Stents
Explore Article Circulation (Jul 9 2010)
Background— Stent thrombosis (ST) after sirolimus-eluting stent implantation has not yet been adequately characterized, mainly because of its low incidence. Methods and Results— The Registry of Stent Thrombosis for Review and Reevaluation (RESTART) is a Japanese nationwide registry of sirolimus-eluting stent–associated ST comprising 611 patients with definite ST (early [within 30 days; EST], 322 patients; late [between 31 and 365 days; LST], 105 patients; and very late [>1 year; VLST], 184 patients). Baseline demographics, clinical presentation, and long-term outcome of sirolimus-eluting stent–associated ST were compared among patients with EST, LST, and VLST. Baseline demographics were significantly different according to the ...
Comment on Article Mentions: Stanford University Kyoto University Graduate School of Medicine Yasuhiro Honda
RSS Feed
Recent Comments
Eric Swanson » Jim Fujimoto video: Biophotonics and optical coherence tomography
Great video Jim!
dariemihaela » Gary S. Mintz
Dear Prof. Dr. Gary S. Mintz, You are an extraordinary expert in imaging, an intelligence ...
See all recent comments